View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsIBEX Technologies 配当と自社株買い配当金 基準チェック /06IBEX Technologies配当金を支払った記録がありません。主要情報n/a配当利回り0.7%バイバック利回り総株主利回り0.7%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 12The Common Shares of IBEX Technologies to Be Delisted from TSX Venture Exchange, in Connection with the Completion of the Amalgamation and Effective at the Close of Business on April 11, 2024TSX Venture Exchange has accepted for filing an acquisition agreement dated February 9, 2024 between IBEX Technologies Inc. (the Company) and an arm's length third party (the "Acquirer") pursuant to which the Acquirer acquired all of the issued and outstanding common shares of the Company by way of an amalgamation under the Canada Business Corporations Act (the "CBCA") (the "Amalgamation"). In connection with the completion of the Amalgamation and effective at the close of business on April 11, 2024, the common shares of the Company will be delisted from TSX Venture Exchange.お知らせ • Apr 09+ 1 more updateBBI Solutions OEM Limited completed the acquisition of IBEX Technologies Inc. (TSXV:IBT) from Milfam LLC, McLean Capital Inc., Paul Baehr and others.BBI Solutions OEM Limited entered into a binding acquisition agreement to acquire IBEX Technologies Inc. (TSXV:IBT) from Milfam LLC, McLean Capital Inc., Paul Baehr and others for CAD 35.5 million on February 9, 2024. BBI will acquire all of the issued and outstanding shares of IBEX at a price of CAD 1.45 per share in cash. Under the amalgamation, each issued and outstanding common share of IBEX will be exchanged for one redeemable preferred share of Amalco, which will immediately be redeemed for CAD 1.45 cash per share. The total consideration is approximately CAD 37.9 million. Upon completion of the amalgamation, shareholders will cease to hold shares of IBEX and IBEX will be delisted from the TSX Venture Exchange. If BBI Solutions termination fee event occurs pursuant to Section 9.2(c)(i) of the acquisition agreement, the BBI Solutions shall pay IBEX the termination fee of CAD 0.97 million and if IBEX termination fee event occurs, IBEX shall pay the BBI Solutions the termination fee of CAD 1.894 million to BBI Solutions in accordance with Section 10.2(b) of the acquisition agreement. The amalgamation is subject to approval by at least two-thirds of the votes cast by IBEX shareholders present in person or represented by proxy and entitled to vote at the Meeting and is subject to third party approval. The Board of Directors of IBEX, after consultation with its financial and legal advisors, has unanimously approved entering into the acquisition agreement. Paul Baehr, Chairman, President and Chief Executive Officer of IBEX, and all of IBEX’s other directors and senior officers, holding in the aggregate approximately 10.39% of IBEX’s outstanding shares, have entered into Support and Voting Agreements with the Purchaser under which they have each agreed irrevocably to support and vote their shares in favour of the amalgamation. In addition, McLean Capital Inc. of Laval, Québec, and entities managed and advised by MILFAM LLC, holding in the aggregate approximately 36.76% of IBEX’s outstanding shares, have entered into similar Support and Voting Agreements with the Purchaser under which they have each agreed irrevocably to support and vote their shares in favour of the Amalgamation. As a result, shareholders holding in the aggregate approximately 47.15% of IBEX’s outstanding shares have entered into Support and Voting Agreements with the Purchaser. The amalgamation was approved by IBEX shareholders at an annual and special meeting held on April 3, 2024. Closing of the amalgamation is expected to take place on April 8, 2024.Fort Capital Partners provided a fairness opinion to the Board of Directors of IBEX in connection with the Amalgamation. Laurel Hill Advisory Group has been retained as IBEX’s shareholder communications advisor and will receive a fee of CAD 0.05 million for its services. Fasken Martineau DuMoulin LLP is acting as legal counsel to IBEX in connection with the amalgamation. Computershare Investor Services Inc. acted as depositary and transfer agent to IBEX.BBI Solutions OEM Limited completed the acquisition of IBEX Technologies Inc. (TSXV:IBT) from Milfam LLC, McLean Capital Inc., Paul Baehr and others on April 8, 2024. In connection with the sale, IBEX has applied for delisting from the TSX Venture Exchange, which is expected to occur on or about April 11, 2024.お知らせ • Mar 25IBEX Technologies Provides Delisting UpdateIBEX Technologies Inc. has entered into an agreement for the sale of the company. Subject to shareholder approval on April 3, 2024, the transaction is expected to close on April 8, 2024, following which the company will be delisted from the TSX Venture Exchange.お知らせ • Feb 14+ 1 more updateIBEX Technologies to Delist from TSX-VIBEX Technologies Inc, has announced that it has entered into a binding acquisition agreement dated February 9, 2024 (the "Acquisition Agreement") and related agreements with 15720273 Canada Inc. (the "Purchaser"), a newly incorporated, wholly-owned subsidiary of BBI Solutions OEM Limited ("BBI"), whereby BBI will acquire all of the issued and outstanding shares of IBEX at a price of $1.45 per share in cash. Upon completion of the Amalgamation, shareholders will cease to hold shares of IBEX and IBEX will be delisted from the TSX Venture Exchange.分析記事 • Feb 13The Market Lifts IBEX Technologies Inc. (CVE:IBT) Shares 27% But It Can Do MoreDespite an already strong run, IBEX Technologies Inc. ( CVE:IBT ) shares have been powering on, with a gain of 27% in...New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (77% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (CA$27.5m market cap, or US$20.4m).Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improves as stock rises 26%After last week's 26% share price gain to CA$1.41, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 17x in the Biotechs industry in North America. Total returns to shareholders of 348% over the past three years.分析記事 • Dec 22IBEX Technologies' (CVE:IBT) Earnings Might Not Be As Promising As They SeemFollowing the release of a positive earnings report recently, IBEX Technologies Inc.'s ( CVE:IBT ) stock performed...分析記事 • Dec 19Market Might Still Lack Some Conviction On IBEX Technologies Inc. (CVE:IBT) Even After 28% Share Price BoostThose holding IBEX Technologies Inc. ( CVE:IBT ) shares would be relieved that the share price has rebounded 28% in the...Reported Earnings • Dec 15First quarter 2024 earnings released: EPS: CA$0.03 (vs CA$0.03 in 1Q 2023)First quarter 2024 results: EPS: CA$0.03 (in line with 1Q 2023). Revenue: CA$2.06m (up 18% from 1Q 2023). Net income: CA$810.3k (up 19% from 1Q 2023). Profit margin: 39% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Dec 15IBEX Technologies Inc. Provides Earnings Guidance for the Fiscal Year 2024IBEX Technologies Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the fiscal year 2023 range, with continued strong growth in the hemostasis business. Earnings before tax to be in line with the fiscal year 2023.お知らせ • Nov 18IBEX Technologies Inc., Annual General Meeting, Jan 24, 2024IBEX Technologies Inc., Annual General Meeting, Jan 24, 2024.分析記事 • Oct 05Calculating The Fair Value Of IBEX Technologies Inc. (CVE:IBT)Key Insights Using the 2 Stage Free Cash Flow to Equity, IBEX Technologies fair value estimate is CA$0.99 With CA$0.99...Valuation Update With 7 Day Price Move • Jun 30Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CA$1.12, the stock trades at a trailing P/E ratio of 16.3x. Average trailing P/E is 14x in the Biotechs industry in North America. Total returns to shareholders of 300% over the past three years.New Risk • Jun 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (26% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (CA$22.8m market cap, or US$17.2m).Valuation Update With 7 Day Price Move • Jun 15Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CA$1.14, the stock trades at a trailing P/E ratio of 16.6x. Average trailing P/E is 12x in the Biotechs industry in North America. Total returns to shareholders of 375% over the past three years.New Risk • Jun 08New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 26% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (26% accrual ratio). Minor Risk Market cap is less than US$100m (CA$21.1m market cap, or US$15.8m).Reported Earnings • Jun 08Third quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.02 in 3Q 2022)Third quarter 2023 results: EPS: CA$0.03 (up from CA$0.02 in 3Q 2022). Revenue: CA$2.26m (up 2.5% from 3Q 2022). Net income: CA$891.4k (up 56% from 3Q 2022). Profit margin: 39% (up from 26% in 3Q 2022). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • May 22A Look At The Fair Value Of IBEX Technologies Inc. (CVE:IBT)Key Insights IBEX Technologies' estimated fair value is CA$0.74 based on 2 Stage Free Cash Flow to Equity Current share...Reported Earnings • Mar 21Second quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.02 in 2Q 2022)Second quarter 2023 results: EPS: CA$0.003 (down from CA$0.02 in 2Q 2022). Revenue: CA$1.72m (down 6.0% from 2Q 2022). Net income: CA$100.0k (down 75% from 2Q 2022). Profit margin: 5.8% (down from 22% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has increased by 99% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Jan 19Shareholders May Be More Conservative With IBEX Technologies Inc.'s (CVE:IBT) CEO Compensation For NowKey Insights IBEX Technologies to hold its Annual General Meeting on 25 January 2023 CEO Paul Baehr's total...Reported Earnings • Dec 16First quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.03 in 1Q 2022)First quarter 2023 results: EPS: CA$0.03 (in line with 1Q 2022). Revenue: CA$1.75m (down 1.7% from 1Q 2022). Net income: CA$678.5k (up 2.1% from 1Q 2022). Profit margin: 39% (up from 37% in 1Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 69% per year whereas the company’s share price has increased by 71% per year.お知らせ • Nov 19IBEX Technologies Inc., Annual General Meeting, Jan 25, 2023IBEX Technologies Inc., Annual General Meeting, Jan 25, 2023.Reported Earnings • Nov 16Full year 2022 earnings released: EPS: CA$0.067 (vs CA$0.031 in FY 2021)Full year 2022 results: EPS: CA$0.067 (up from CA$0.031 in FY 2021). Revenue: CA$7.89m (up 49% from FY 2021). Net income: CA$1.67m (up 120% from FY 2021). Profit margin: 21% (up from 14% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 64% per year, which means it is significantly lagging earnings growth.Reported Earnings • Jun 11Third quarter 2022 earnings released: EPS: CA$0.02 (vs CA$0.014 in 3Q 2021)Third quarter 2022 results: EPS: CA$0.02 (up from CA$0.014 in 3Q 2021). Revenue: CA$2.21m (up 51% from 3Q 2021). Net income: CA$569.6k (up 71% from 3Q 2021). Profit margin: 26% (up from 23% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has only increased by 58% per year, which means it is significantly lagging earnings growth.Reported Earnings • Mar 19Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: CA$0.02 (up from CA$0.012 in 2Q 2021). Revenue: CA$1.83m (up 40% from 2Q 2021). Net income: CA$405.5k (up 63% from 2Q 2021). Profit margin: 22% (up from 19% in 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.分析記事 • Feb 10We Think Shareholders Will Probably Be Generous With IBEX Technologies Inc.'s (CVE:IBT) CEO CompensationWe have been pretty impressed with the performance at IBEX Technologies Inc. ( CVE:IBT ) recently and CEO Paul Baehr...Reported Earnings • Dec 17First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: EPS: CA$0.03 (up from CA$0.01 in 1Q 2021). Revenue: CA$1.78m (up 53% from 1Q 2021). Net income: CA$664.6k (up 343% from 1Q 2021). Profit margin: 37% (up from 13% in 1Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth.Board Change • Jul 31High number of new directorsDirector Christine Charette was the last director to join the board, commencing their role in 2021.Reported Earnings • Jun 19Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CA$1.47m (down 13% from 3Q 2020). Net income: CA$333.5k (down 47% from 3Q 2020). Profit margin: 23% (down from 37% in 3Q 2020). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 12% per year.分析記事 • Mar 25Investors Shouldn't Be Too Comfortable With IBEX Technologies' (CVE:IBT) Robust EarningsIBEX Technologies Inc.'s ( CVE:IBT ) robust earnings report didn't manage to move the market for its stock. Our...Reported Earnings • Mar 20Second quarter 2021 earnings released: EPS CA$0.012 (vs CA$0.001 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CA$1.31m (up 31% from 2Q 2020). Net income: CA$248.5k (up CA$277.5k from 2Q 2020). Profit margin: 19% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.分析記事 • Feb 22IBEX Technologies Inc.'s (CVE:IBT) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?IBEX Technologies' (CVE:IBT) stock is up by a considerable 11% over the past month. Given that stock prices are usually...Is New 90 Day High Low • Feb 10New 90-day high: CA$0.30The company is up 13% from its price of CA$0.27 on 11 November 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 30% over the same period.分析記事 • Dec 29How Should Investors React To IBEX Technologies' (CVE:IBT) CEO Pay?Paul Baehr is the CEO of IBEX Technologies Inc. ( CVE:IBT ), and in this article, we analyze the executive's...お知らせ • Nov 14IBEX Technologies Inc., Annual General Meeting, Jan 20, 2021IBEX Technologies Inc., Annual General Meeting, Jan 20, 2021.Reported Earnings • Nov 07Full year 2020 earnings released: EPS CA$0.04The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CA$5.21m (up 21% from FY 2019). Net income: CA$965.7k (up CA$2.23m from FY 2019). Profit margin: 19% (up from net loss in FY 2019). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 93% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Nov 07New 90-day high: CA$0.30The company is up 45% from its price of CA$0.21 on 07 August 2020. The Canadian market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 7.0% over the same period.お知らせ • Oct 01+ 1 more updateIbex Technologies Inc. Announces Executive ChangesIBEX Technologies Inc. announced that Belinda Franco, CPA, CA has joined IBEX and will become director of finance. Belinda will work with Richard Collin, company Director of Finance and Chief Financial Officer, during a transition period and will replace Richard after company complete company audited financial statements for the fiscal year ended July 31, 2020.決済の安定と成長配当データの取得安定した配当: IBTの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: IBTの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場IBEX Technologies 配当利回り対市場IBT 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (IBT)n/a市場下位25% (CA)1.7%市場トップ25% (CA)5.4%業界平均 (Biotechs)2.4%アナリスト予想 (IBT) (最長3年)n/a注目すべき配当: IBTは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: IBTは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: IBTの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: IBTが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YCA 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/04/08 14:30終値2024/04/08 00:00収益2024/01/31年間収益2023/07/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋IBEX Technologies Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 12The Common Shares of IBEX Technologies to Be Delisted from TSX Venture Exchange, in Connection with the Completion of the Amalgamation and Effective at the Close of Business on April 11, 2024TSX Venture Exchange has accepted for filing an acquisition agreement dated February 9, 2024 between IBEX Technologies Inc. (the Company) and an arm's length third party (the "Acquirer") pursuant to which the Acquirer acquired all of the issued and outstanding common shares of the Company by way of an amalgamation under the Canada Business Corporations Act (the "CBCA") (the "Amalgamation"). In connection with the completion of the Amalgamation and effective at the close of business on April 11, 2024, the common shares of the Company will be delisted from TSX Venture Exchange.
お知らせ • Apr 09+ 1 more updateBBI Solutions OEM Limited completed the acquisition of IBEX Technologies Inc. (TSXV:IBT) from Milfam LLC, McLean Capital Inc., Paul Baehr and others.BBI Solutions OEM Limited entered into a binding acquisition agreement to acquire IBEX Technologies Inc. (TSXV:IBT) from Milfam LLC, McLean Capital Inc., Paul Baehr and others for CAD 35.5 million on February 9, 2024. BBI will acquire all of the issued and outstanding shares of IBEX at a price of CAD 1.45 per share in cash. Under the amalgamation, each issued and outstanding common share of IBEX will be exchanged for one redeemable preferred share of Amalco, which will immediately be redeemed for CAD 1.45 cash per share. The total consideration is approximately CAD 37.9 million. Upon completion of the amalgamation, shareholders will cease to hold shares of IBEX and IBEX will be delisted from the TSX Venture Exchange. If BBI Solutions termination fee event occurs pursuant to Section 9.2(c)(i) of the acquisition agreement, the BBI Solutions shall pay IBEX the termination fee of CAD 0.97 million and if IBEX termination fee event occurs, IBEX shall pay the BBI Solutions the termination fee of CAD 1.894 million to BBI Solutions in accordance with Section 10.2(b) of the acquisition agreement. The amalgamation is subject to approval by at least two-thirds of the votes cast by IBEX shareholders present in person or represented by proxy and entitled to vote at the Meeting and is subject to third party approval. The Board of Directors of IBEX, after consultation with its financial and legal advisors, has unanimously approved entering into the acquisition agreement. Paul Baehr, Chairman, President and Chief Executive Officer of IBEX, and all of IBEX’s other directors and senior officers, holding in the aggregate approximately 10.39% of IBEX’s outstanding shares, have entered into Support and Voting Agreements with the Purchaser under which they have each agreed irrevocably to support and vote their shares in favour of the amalgamation. In addition, McLean Capital Inc. of Laval, Québec, and entities managed and advised by MILFAM LLC, holding in the aggregate approximately 36.76% of IBEX’s outstanding shares, have entered into similar Support and Voting Agreements with the Purchaser under which they have each agreed irrevocably to support and vote their shares in favour of the Amalgamation. As a result, shareholders holding in the aggregate approximately 47.15% of IBEX’s outstanding shares have entered into Support and Voting Agreements with the Purchaser. The amalgamation was approved by IBEX shareholders at an annual and special meeting held on April 3, 2024. Closing of the amalgamation is expected to take place on April 8, 2024.Fort Capital Partners provided a fairness opinion to the Board of Directors of IBEX in connection with the Amalgamation. Laurel Hill Advisory Group has been retained as IBEX’s shareholder communications advisor and will receive a fee of CAD 0.05 million for its services. Fasken Martineau DuMoulin LLP is acting as legal counsel to IBEX in connection with the amalgamation. Computershare Investor Services Inc. acted as depositary and transfer agent to IBEX.BBI Solutions OEM Limited completed the acquisition of IBEX Technologies Inc. (TSXV:IBT) from Milfam LLC, McLean Capital Inc., Paul Baehr and others on April 8, 2024. In connection with the sale, IBEX has applied for delisting from the TSX Venture Exchange, which is expected to occur on or about April 11, 2024.
お知らせ • Mar 25IBEX Technologies Provides Delisting UpdateIBEX Technologies Inc. has entered into an agreement for the sale of the company. Subject to shareholder approval on April 3, 2024, the transaction is expected to close on April 8, 2024, following which the company will be delisted from the TSX Venture Exchange.
お知らせ • Feb 14+ 1 more updateIBEX Technologies to Delist from TSX-VIBEX Technologies Inc, has announced that it has entered into a binding acquisition agreement dated February 9, 2024 (the "Acquisition Agreement") and related agreements with 15720273 Canada Inc. (the "Purchaser"), a newly incorporated, wholly-owned subsidiary of BBI Solutions OEM Limited ("BBI"), whereby BBI will acquire all of the issued and outstanding shares of IBEX at a price of $1.45 per share in cash. Upon completion of the Amalgamation, shareholders will cease to hold shares of IBEX and IBEX will be delisted from the TSX Venture Exchange.
分析記事 • Feb 13The Market Lifts IBEX Technologies Inc. (CVE:IBT) Shares 27% But It Can Do MoreDespite an already strong run, IBEX Technologies Inc. ( CVE:IBT ) shares have been powering on, with a gain of 27% in...
New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (77% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (CA$27.5m market cap, or US$20.4m).
Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improves as stock rises 26%After last week's 26% share price gain to CA$1.41, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 17x in the Biotechs industry in North America. Total returns to shareholders of 348% over the past three years.
分析記事 • Dec 22IBEX Technologies' (CVE:IBT) Earnings Might Not Be As Promising As They SeemFollowing the release of a positive earnings report recently, IBEX Technologies Inc.'s ( CVE:IBT ) stock performed...
分析記事 • Dec 19Market Might Still Lack Some Conviction On IBEX Technologies Inc. (CVE:IBT) Even After 28% Share Price BoostThose holding IBEX Technologies Inc. ( CVE:IBT ) shares would be relieved that the share price has rebounded 28% in the...
Reported Earnings • Dec 15First quarter 2024 earnings released: EPS: CA$0.03 (vs CA$0.03 in 1Q 2023)First quarter 2024 results: EPS: CA$0.03 (in line with 1Q 2023). Revenue: CA$2.06m (up 18% from 1Q 2023). Net income: CA$810.3k (up 19% from 1Q 2023). Profit margin: 39% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Dec 15IBEX Technologies Inc. Provides Earnings Guidance for the Fiscal Year 2024IBEX Technologies Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the fiscal year 2023 range, with continued strong growth in the hemostasis business. Earnings before tax to be in line with the fiscal year 2023.
お知らせ • Nov 18IBEX Technologies Inc., Annual General Meeting, Jan 24, 2024IBEX Technologies Inc., Annual General Meeting, Jan 24, 2024.
分析記事 • Oct 05Calculating The Fair Value Of IBEX Technologies Inc. (CVE:IBT)Key Insights Using the 2 Stage Free Cash Flow to Equity, IBEX Technologies fair value estimate is CA$0.99 With CA$0.99...
Valuation Update With 7 Day Price Move • Jun 30Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CA$1.12, the stock trades at a trailing P/E ratio of 16.3x. Average trailing P/E is 14x in the Biotechs industry in North America. Total returns to shareholders of 300% over the past three years.
New Risk • Jun 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (26% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (CA$22.8m market cap, or US$17.2m).
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CA$1.14, the stock trades at a trailing P/E ratio of 16.6x. Average trailing P/E is 12x in the Biotechs industry in North America. Total returns to shareholders of 375% over the past three years.
New Risk • Jun 08New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 26% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (26% accrual ratio). Minor Risk Market cap is less than US$100m (CA$21.1m market cap, or US$15.8m).
Reported Earnings • Jun 08Third quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.02 in 3Q 2022)Third quarter 2023 results: EPS: CA$0.03 (up from CA$0.02 in 3Q 2022). Revenue: CA$2.26m (up 2.5% from 3Q 2022). Net income: CA$891.4k (up 56% from 3Q 2022). Profit margin: 39% (up from 26% in 3Q 2022). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • May 22A Look At The Fair Value Of IBEX Technologies Inc. (CVE:IBT)Key Insights IBEX Technologies' estimated fair value is CA$0.74 based on 2 Stage Free Cash Flow to Equity Current share...
Reported Earnings • Mar 21Second quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.02 in 2Q 2022)Second quarter 2023 results: EPS: CA$0.003 (down from CA$0.02 in 2Q 2022). Revenue: CA$1.72m (down 6.0% from 2Q 2022). Net income: CA$100.0k (down 75% from 2Q 2022). Profit margin: 5.8% (down from 22% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has increased by 99% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Jan 19Shareholders May Be More Conservative With IBEX Technologies Inc.'s (CVE:IBT) CEO Compensation For NowKey Insights IBEX Technologies to hold its Annual General Meeting on 25 January 2023 CEO Paul Baehr's total...
Reported Earnings • Dec 16First quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.03 in 1Q 2022)First quarter 2023 results: EPS: CA$0.03 (in line with 1Q 2022). Revenue: CA$1.75m (down 1.7% from 1Q 2022). Net income: CA$678.5k (up 2.1% from 1Q 2022). Profit margin: 39% (up from 37% in 1Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 69% per year whereas the company’s share price has increased by 71% per year.
お知らせ • Nov 19IBEX Technologies Inc., Annual General Meeting, Jan 25, 2023IBEX Technologies Inc., Annual General Meeting, Jan 25, 2023.
Reported Earnings • Nov 16Full year 2022 earnings released: EPS: CA$0.067 (vs CA$0.031 in FY 2021)Full year 2022 results: EPS: CA$0.067 (up from CA$0.031 in FY 2021). Revenue: CA$7.89m (up 49% from FY 2021). Net income: CA$1.67m (up 120% from FY 2021). Profit margin: 21% (up from 14% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has only increased by 64% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Jun 11Third quarter 2022 earnings released: EPS: CA$0.02 (vs CA$0.014 in 3Q 2021)Third quarter 2022 results: EPS: CA$0.02 (up from CA$0.014 in 3Q 2021). Revenue: CA$2.21m (up 51% from 3Q 2021). Net income: CA$569.6k (up 71% from 3Q 2021). Profit margin: 26% (up from 23% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has only increased by 58% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Mar 19Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: CA$0.02 (up from CA$0.012 in 2Q 2021). Revenue: CA$1.83m (up 40% from 2Q 2021). Net income: CA$405.5k (up 63% from 2Q 2021). Profit margin: 22% (up from 19% in 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.
分析記事 • Feb 10We Think Shareholders Will Probably Be Generous With IBEX Technologies Inc.'s (CVE:IBT) CEO CompensationWe have been pretty impressed with the performance at IBEX Technologies Inc. ( CVE:IBT ) recently and CEO Paul Baehr...
Reported Earnings • Dec 17First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: EPS: CA$0.03 (up from CA$0.01 in 1Q 2021). Revenue: CA$1.78m (up 53% from 1Q 2021). Net income: CA$664.6k (up 343% from 1Q 2021). Profit margin: 37% (up from 13% in 1Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth.
Board Change • Jul 31High number of new directorsDirector Christine Charette was the last director to join the board, commencing their role in 2021.
Reported Earnings • Jun 19Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CA$1.47m (down 13% from 3Q 2020). Net income: CA$333.5k (down 47% from 3Q 2020). Profit margin: 23% (down from 37% in 3Q 2020). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 12% per year.
分析記事 • Mar 25Investors Shouldn't Be Too Comfortable With IBEX Technologies' (CVE:IBT) Robust EarningsIBEX Technologies Inc.'s ( CVE:IBT ) robust earnings report didn't manage to move the market for its stock. Our...
Reported Earnings • Mar 20Second quarter 2021 earnings released: EPS CA$0.012 (vs CA$0.001 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CA$1.31m (up 31% from 2Q 2020). Net income: CA$248.5k (up CA$277.5k from 2Q 2020). Profit margin: 19% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
分析記事 • Feb 22IBEX Technologies Inc.'s (CVE:IBT) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?IBEX Technologies' (CVE:IBT) stock is up by a considerable 11% over the past month. Given that stock prices are usually...
Is New 90 Day High Low • Feb 10New 90-day high: CA$0.30The company is up 13% from its price of CA$0.27 on 11 November 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 30% over the same period.
分析記事 • Dec 29How Should Investors React To IBEX Technologies' (CVE:IBT) CEO Pay?Paul Baehr is the CEO of IBEX Technologies Inc. ( CVE:IBT ), and in this article, we analyze the executive's...
お知らせ • Nov 14IBEX Technologies Inc., Annual General Meeting, Jan 20, 2021IBEX Technologies Inc., Annual General Meeting, Jan 20, 2021.
Reported Earnings • Nov 07Full year 2020 earnings released: EPS CA$0.04The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CA$5.21m (up 21% from FY 2019). Net income: CA$965.7k (up CA$2.23m from FY 2019). Profit margin: 19% (up from net loss in FY 2019). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 93% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Nov 07New 90-day high: CA$0.30The company is up 45% from its price of CA$0.21 on 07 August 2020. The Canadian market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 7.0% over the same period.
お知らせ • Oct 01+ 1 more updateIbex Technologies Inc. Announces Executive ChangesIBEX Technologies Inc. announced that Belinda Franco, CPA, CA has joined IBEX and will become director of finance. Belinda will work with Richard Collin, company Director of Finance and Chief Financial Officer, during a transition period and will replace Richard after company complete company audited financial statements for the fiscal year ended July 31, 2020.